A genome-based survey of invasive pneumococci in Norway over four decades reveals lineage-specific responses to vaccination.
Archival isolates
Global pneumococcal sequencing clusters
Invasive pneumococcal disease
Penicillin resistance
Pneumococcal conjugate vaccine
Population dynamics
Serotype replacement
Streptococcus pneumoniae
Whole-genome sequencing
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
10
05
2024
accepted:
15
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Streptococcus pneumoniae is a major cause of mortality globally. The introduction of pneumococcal conjugate vaccines (PCVs) has reduced the incidence of the targeted serotypes significantly, but expansion of non-targeted serotypes, serotype replacement, and incomplete vaccine-targeting contribute to pneumococcal disease in the vaccine era. Here, we characterize the changing population genetic landscape of S. pneumoniae in Norway over a 41-year period (1982-2022). Since 2018, all cases of invasive pneumococcal disease have undergone whole-genome sequencing (WGS) at the Norwegian Institute of Public Health. In order to characterize the changing population over time, historical isolates were re-cultured and sequenced, resulting in a historical WGS dataset. Isolates were assigned to global pneumococcal sequence clusters (GPSCs) using PathogenWatch and assigned to serotypes using in silico (SeroBA) and in vitro methods (Quellung reaction). Temporal phylogenetic analyses were performed on GPSCs of particular interest. The availability of WGS data allowed us to study capsular variation at the level of individual lineages. We detect highly divergent fates for different GPSCs following the introduction of PCVs. For two out of eight major GPSCs, we identified multiple instances of serotype switching from vaccine types to non-vaccine types. Dating analyses suggest that most instances of serotype switching predated the introduction of PCVs, but expansion occurred after their introduction. Furthermore, selection for penicillin non-susceptibility was not a driving force for the changing serotype distribution within the GPSCs over time. PCVs have been major shapers of the Norwegian disease-causing pneumococcal population, both at the level of serotype distributions and the underlying lineage dynamics. Overall, the introduction of PCVs has reduced the incidence of invasive disease. However, some GPSCs initially dominated by vaccine types escaped the effect of vaccination through expansion of non-vaccine serotypes. Close monitoring of circulating lineages and serotypes will be key for ensuring optimal vaccination coverage going forward.
Sections du résumé
BACKGROUND
BACKGROUND
Streptococcus pneumoniae is a major cause of mortality globally. The introduction of pneumococcal conjugate vaccines (PCVs) has reduced the incidence of the targeted serotypes significantly, but expansion of non-targeted serotypes, serotype replacement, and incomplete vaccine-targeting contribute to pneumococcal disease in the vaccine era. Here, we characterize the changing population genetic landscape of S. pneumoniae in Norway over a 41-year period (1982-2022).
METHODS
METHODS
Since 2018, all cases of invasive pneumococcal disease have undergone whole-genome sequencing (WGS) at the Norwegian Institute of Public Health. In order to characterize the changing population over time, historical isolates were re-cultured and sequenced, resulting in a historical WGS dataset. Isolates were assigned to global pneumococcal sequence clusters (GPSCs) using PathogenWatch and assigned to serotypes using in silico (SeroBA) and in vitro methods (Quellung reaction). Temporal phylogenetic analyses were performed on GPSCs of particular interest.
RESULTS
RESULTS
The availability of WGS data allowed us to study capsular variation at the level of individual lineages. We detect highly divergent fates for different GPSCs following the introduction of PCVs. For two out of eight major GPSCs, we identified multiple instances of serotype switching from vaccine types to non-vaccine types. Dating analyses suggest that most instances of serotype switching predated the introduction of PCVs, but expansion occurred after their introduction. Furthermore, selection for penicillin non-susceptibility was not a driving force for the changing serotype distribution within the GPSCs over time.
CONCLUSIONS
CONCLUSIONS
PCVs have been major shapers of the Norwegian disease-causing pneumococcal population, both at the level of serotype distributions and the underlying lineage dynamics. Overall, the introduction of PCVs has reduced the incidence of invasive disease. However, some GPSCs initially dominated by vaccine types escaped the effect of vaccination through expansion of non-vaccine serotypes. Close monitoring of circulating lineages and serotypes will be key for ensuring optimal vaccination coverage going forward.
Identifiants
pubmed: 39456053
doi: 10.1186/s13073-024-01396-3
pii: 10.1186/s13073-024-01396-3
doi:
Substances chimiques
Pneumococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Informations de copyright
© 2024. The Author(s).
Références
Winje BA, Vestrheim DF, White RA, Steens A. The risk of invasive pneumococcal disease differs between risk groups in Norway following widespread use of the 13-valent pneumococcal vaccine in children. Microorganisms. 2021;9. https://doi.org/10.3390/microorganisms9081774 .
Løvlie A, Vestrheim DF, Aaberge IS, Steens A. Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13. BMC Infect Dis. 2020;20:29.
doi: 10.1186/s12879-019-4754-0
pubmed: 31924177
pmcid: 6954625
Vaxneuvance pneumococcal polysaccharide conjugate vaccine, authorisation note. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxneuvance . Cited 2024 Apr 17.
Prevenar 20 pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), authorisation note. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-20-previously-apexxnar . Cited 2024 Apr 17.
Kapatai G, Sheppard CL, Al-Shahib A, Litt DJ, Underwood AP, Harrison TG, et al. Whole genome sequencing of Streptococcus pneumoniae: development, evaluation and verification of targets for serogroup and serotype prediction using an automated pipeline. PeerJ. 2016;4: e2477.
doi: 10.7717/peerj.2477
pubmed: 27672516
pmcid: 5028725
Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins M, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2006;2. Available from: https://pubmed.ncbi.nlm.nih.gov/16532061/ . Cited 2024 Mar 3.
Croucher NJ, Kagedan L, Thompson CM, Parkhill J, Bentley SD, Finkelstein JA, et al. Selective and genetic constraints on pneumococcal serotype switching. PLoS Genet. 2015;11: e1005095.
doi: 10.1371/journal.pgen.1005095
pubmed: 25826208
pmcid: 4380333
Bradshaw JL, Rafiqullah IM, Robinson DA, McDaniel LS. Transformation of nonencapsulated Streptococcus pneumoniae during systemic infection. Sci Rep. 2020;10:18932.
doi: 10.1038/s41598-020-75988-5
pubmed: 33144660
pmcid: 7641166
Croucher NJ, Hanage WP, Harris SR, McGee L, van der Linden M, de Lencastre H, et al. Variable recombination dynamics during the emergence, transmission and “disarming” of a multidrug-resistant pneumococcal clone. BMC Biol. 2014;12:49.
doi: 10.1186/1741-7007-12-49
pubmed: 24957517
pmcid: 4094930
Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–73.
doi: 10.1016/S0140-6736(10)62225-8
pubmed: 21492929
pmcid: 3256741
Lo SW, Gladstone RA, van Tonder AJ, Lees JA, du Plessis M, Benisty R, et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis. 2019;19:759–69.
doi: 10.1016/S1473-3099(19)30297-X
pubmed: 31196809
pmcid: 7641901
Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: serotype 3 pneumococcal disease. Front Cell Infect Microbiol. 2020;10: 613287.
doi: 10.3389/fcimb.2020.613287
pubmed: 33425786
pmcid: 7786310
Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MCC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225–33.
doi: 10.1128/JCM.02199-06
pubmed: 17267625
pmcid: 1865839
Feemster K, Weaver J, Buchwald U, Banniettis N, Cox KS, McIntosh ED, et al. Pneumococcal vaccine breakthrough and failure in infants and children: a narrative review. Vaccines (Basel). 2023;11. https://doi.org/10.3390/vaccines11121750 .
Corander J, Fraser C, Gutmann MU, Arnold B, Hanage WP, Bentley SD, et al. Frequency-dependent selection in vaccine-associated pneumococcal population dynamics. Nat Ecol Evol. 2017;1:1950–60.
doi: 10.1038/s41559-017-0337-x
pubmed: 29038424
pmcid: 5708525
Gladstone RA, Devine V, Jones J, Cleary D, Jefferies JM, Bentley SD, et al. Pre-vaccine serotype composition within a lineage signposts its serotype replacement - a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK. Microb Genom. 2017;3: e000119.
pubmed: 29026652
pmcid: 5628697
Gladstone RA, Lo SW, Lees JA, Croucher NJ, van Tonder AJ, Corander J, et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine. 2019;43:338–46.
doi: 10.1016/j.ebiom.2019.04.021
pubmed: 31003929
pmcid: 6557916
Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE Jr, Walker H, et al. Validation of β-lactam minimum inhibitory concentration predictions for pneumococcal isolates with newly encountered penicillin binding protein (PBP) sequences. BMC Genomics. 2017;18:621.
doi: 10.1186/s12864-017-4017-7
pubmed: 28810827
pmcid: 5558719
Epping L, van Tonder AJ, Gladstone RA, The Global Pneumococcal Sequencing Consortium, Bentley SD, Page AJ, et al. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. Microb Genom. 2018;4. https://doi.org/10.1099/mgen.0.000186 .
The Global Pneumococcal Sequencing Project. Available from: https://www.pneumogen.net/gps/ .
Pathogenwatch. A global platform for genomic surveillance. Available from: https://www.pathogen.watch .
Monocle data viewer. Available from: https://data-viewer.monocle.sanger.ac.uk/project/gps .
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.
doi: 10.1093/bioinformatics/btu170
pubmed: 24695404
pmcid: 4103590
Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77.
doi: 10.1089/cmb.2012.0021
pubmed: 22506599
pmcid: 3342519
Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW, Weiser JN, et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. Genome Res. 2019;29:304–16.
doi: 10.1101/gr.241455.118
pubmed: 30679308
pmcid: 6360808
GPS tools. Available from: https://www.pneumogen.net .
Wickham H, François R, Henry L, Müller K, Vaughan D. dplyr: a grammar of data manipulation. 2023. Available from: https://dplyr.tidyverse.org .
Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016. See: https://ggplot2.tidyverse.org/authors.html#citation .
Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the tidyverse . J Open Source Softw. 2019:1686. https://doi.org/10.21105/joss.01686 .
Neuwirth E. RColorBrewer: ColorBrewer Palettes. R package version 1.1-3. 2022. Available from: https://doi.org/10.32614/cran.package.rcolorbrewer .
Schwengers O, Jelonek L, Dieckmann MA, Beyvers S, Blom J, Goesmann A. Bakta: rapid and standardized annotation of bacterial genomes via alignment-free sequence identification. Microb Genom. 2021;7. https://doi.org/10.1099/mgen.0.000685 .
Seeman T. Snippy. Available from: https://github.com/tseemann/snippy .
Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res. 2015;43: e15.
doi: 10.1093/nar/gku1196
pubmed: 25414349
Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37:1530–4.
doi: 10.1093/molbev/msaa015
pubmed: 32011700
pmcid: 7182206
Didelot X, Croucher NJ, Bentley SD, Harris SR, Wilson DJ. Bayesian inference of ancestral dates on bacterial phylogenetic trees. Nucleic Acids Res. 2018;46: e134.
doi: 10.1093/nar/gky783
pubmed: 30184106
pmcid: 6294524
Drummond AJ, Suchard MA, Xie Dong, Rambaut A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol. 2012;29:1969–73. https://doi.org/10.1093/molbev/mss075 .
Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR. Phandango: an interactive viewer for bacterial population genomics. Bioinformatics. 2018;34:292–3.
doi: 10.1093/bioinformatics/btx610
pubmed: 29028899
The Norwegian Surveillance System for Communicable Diseases. MSIS-statistikk. Available from: https://www.msis.no/ .
Vestrheim DF, Høiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol. 2010;17:325–34.
doi: 10.1128/CVI.00435-09
pubmed: 20107006
pmcid: 2837970
Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022;40:3963–74.
doi: 10.1016/j.vaccine.2022.05.011
pubmed: 35637067
Groves N, Sheppard CL, Litt D, Rose S, Silva A, Njoku N, et al. Evolution of Streptococcus pneumoniae serotype 3 in England and Wales: a major vaccine evader. Genes. 2019;10. https://doi.org/10.3390/genes10110845 .
Palmborg A, Skovdal M, Molden T, Åhman H, Chen L, Banefelt J. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-a longitudinal study over 10 years based on public surveillance data in the Nordics. PLoS ONE. 2023;18: e0287378.
doi: 10.1371/journal.pone.0287378
pubmed: 37363884
pmcid: 10292715
Swarthout TD, Henrion MYR, Thindwa D, Meiring JE, Mbewe M, Kalizang’Oma A, et al. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study. Lancet Infect Dis. 2022;22:1737–47.
doi: 10.1016/S1473-3099(22)00438-8
pubmed: 36029796
pmcid: 10555849
Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N, et al. High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nat Commun. 2020;11:2222.
doi: 10.1038/s41467-020-15786-9
pubmed: 32376860
pmcid: 7203201
Hanquet G, Krizova P, Dalby T, Ladhani SN, Nuorti JP, Danis K, et al. Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe. Emerg Infect Dis. 2022;28. Available from: https://pubmed.ncbi.nlm.nih.gov/34932457/ . Cited 2024 Feb 27.
Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59. Available from: https://pubmed.ncbi.nlm.nih.gov/25034421/ . Cited 2024 Mar 3.
Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, et al. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011;331:430–4.
doi: 10.1126/science.1198545
pubmed: 21273480
pmcid: 3648787
Paton JC, Trappetti C. Streptococcus pneumoniae capsular polysaccharide. Microbiol Spectr. 2019;7. https://doi.org/10.1128/microbiolspec.GPP3-0019-2018 .
van Tonder AJ, Bray JE, Quirk SJ, Haraldsson G, Jolley KA, Maiden MCJ, et al. Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes. Microbial Genomics. 2016;2: e000090.
pubmed: 28133541
pmcid: 5266551
Gladstone RA, Lo SW, Goater R, Yeats C, Taylor B, Hadfield J, et al. Visualizing variation within Global Pneumococcal Sequence Clusters (GPSCs) and country population snapshots to contextualize pneumococcal isolates. Microb Genom. 2020;6. https://doi.org/10.1099/mgen.0.000357 .
Lo SW, Mellor K, Cohen R, Alonso AR, Belman S, Kumar N, et al. Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study. Lancet Microbe. 2022;3:e735–43.
doi: 10.1016/S2666-5247(22)00158-6
pubmed: 35985351
pmcid: 9519462
Belman S, Pesonen H, Croucher NJ, Bentley SD, Corander J. Estimating between country migration in pneumococcal populations. G3. 2024. https://doi.org/10.1093/g3journal/jkae058 .
doi: 10.1093/g3journal/jkae058
pubmed: 38507601
pmcid: 11152062
Belman S, Lefrancq N, Nzenze S, Downs S, du Plessis M, Lo S, et al. Geographic migration and vaccine-induced fitness changes of Streptococcus pneumoniae. bioRxiv. 2023. https://doi.org/10.1101/2023.01.18.524577 .
Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A, Pollard AJ, et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathog. 2018;14: e1007438.
doi: 10.1371/journal.ppat.1007438
pubmed: 30475919
pmcid: 6283594
Bertran M, D’Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24:546–56.
doi: 10.1016/S1473-3099(23)00706-5
pubmed: 38310905
Løchen A, Truscott JE, Croucher NJ. Analysing pneumococcal invasiveness using Bayesian models of pathogen progression rates. bioRxiv. 2021. p. 2021.09.01.458483. Available from: https://www.biorxiv.org/content/10.1101/2021.09.01.458483v1 . Cited 2021 Oct 26.
Yamba Yamba L, Uddén F, Fuursted K, Ahl J, Slotved H-C, Riesbeck K. Extensive/multidrug-resistant pneumococci detected in clinical respiratory tract samples in Southern Sweden are closely related to international multidrug-resistant lineages. Front Cell Infect Microbiol. 2022;12: 824449.
doi: 10.3389/fcimb.2022.824449
pubmed: 35392607
pmcid: 8981583
Ouldali N, Levy C, Varon E, Bonacorsi S, Béchet S, Cohen R, et al. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infect Dis. 2018;18. Available from: https://pubmed.ncbi.nlm.nih.gov/30049623/ . Cited 2024 Mar 8.
Ubukata K, Takata M, Morozumi M, Chiba N, Wajima T, Hanada S, et al. Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010–2017. Emerg Infect Dis. 2018;24:2010–20.
doi: 10.3201/eid2411.180326
pubmed: 30334707
pmcid: 6200004